Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-03-14

Clinical Trial Update: Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress [Phase 1]

View source ↗

Summary

Phase 1 clinical trial investigating oxytocin for reducing substance use disorders associated with chronic stress has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Oxytocin (Oxytocin)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Alcohol Use Disorders | Phase 1 | Status: COMPLETED | Results posted: 2019-03-14